search
Back to results

Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Met DR
Met IR
Placebo
Sponsored by
Elcelyx Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

25 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Is at least 25 years old at Visit 1 (Screening).
  2. Is male, or is female and meets all of the following criteria:

    1. Not breastfeeding
    2. Negative pregnancy test result at Visit 1 (not applicable to post-menopausal or surgically sterile females)
    3. Surgically sterile, postmenopausal, or if of childbearing potential, must practice and be willing to continue to practice appropriate birth control during the entire duration of the study.
  3. Body mass index (BMI) 20.0 to 45.0 kg/m² (inclusive) at Visit 1 (Screening).
  4. Has a physical examination with no clinically significant abnormalities as judged by the investigator.
  5. Has T2DM and an HbA1c of 7.5% to 10.5%, inclusive, at Visit 1.
  6. Has an estimated glomerular filtration rate (eGFR) value of ≥60 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation.
  7. Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 3 months prior to Visit 1:

    1. Thiazolidinedione, sulfonylurea, dipeptidyl peptidase-4 inhibitors, and alpha-glucosidase inhibitors
    2. Hormone replacement therapy (female subjects) and testosterone (male subjects)
    3. Oral contraceptives (female subjects)
    4. Antihypertensive agents
    5. Lipid-lowering agents
    6. Thyroid replacement therapy
    7. Antidepressant agents
  8. Ability to understand and willingness to adhere to protocol requirements.

Exclusion Criteria:

  1. Has a clinically significant medical condition as judged by the investigator that could potentially affect study participation and/or personal well-being, including but not limited to the following conditions:

    1. Hepatic disease
    2. Gastrointestinal disease
    3. Endocrine disorder (T2DM is allowed)
    4. Cardiovascular disease
    5. Central nervous system diseases
    6. Psychiatric or neurological disorders
    7. Organ transplantation
    8. Chronic or acute infection
    9. Orthostatic hypotension, fainting spells or blackouts
    10. Allergy or hypersensitivity.
  2. A history of diabetic ketoacidosis or hyperosmolar non-ketotic hyperglycemia within the past year.
  3. Prior major surgery of any kind within 6 months of Visit 1.
  4. A history of >3% weight change within 3 months of Visit 1.
  5. A clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormality, other than that related to T2DM, judged by the investigator to be clinically significant at Visit 1.
  6. An alanine aminotransferase or aspartate aminotransferase result >2.5 × upper limit of normal (ULN) or a bilirubin result >1.5 × ULN.
  7. A physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study.
  8. Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following excluded medications:

    1. Metformin within 2 months of Visit 1 (Screening)
    2. Insulin within 2 weeks of Visit 1 (Screening) or for more than 1 week within 3 months of Visit 1 (Screening)
    3. Glucagon-like peptide-1 receptor agonists or sodium-glucose co-transporter 2 inhibitors within 3 months of Visit 1
    4. Drugs known to affect body weight, including prescription medications and over-the-counter anti obesity agents within 3 months of Visit 1.
    5. Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption within 3 months of Visit 1
    6. Planned use of any drug treatment that affects gastric pH (prescription or over-the-counter), such as H2-receptor antagonists and proton pump inhibitors, after Visit 2 (Week -2), or planned chronic use of any antacids (i.e., more than twice per week) after Visit 2 (Week -2)
    7. Cationic drugs that are eliminated by renal tubular secretion within 1 week of Visit 1.
    8. Iodinated contrast dye within 1 week prior to Visit 1.
    9. Investigational drug within 2 months (or five half-lives of the investigational drug, whichever is greater) of the date of the first dose of randomized study medication.
    10. Met DR or double-blind matching placebo for Met DR at any time prior to Visit 1 (Screening)
  9. Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures.
  10. Had a blood transfusion or experienced significant blood loss (i.e., >500 mL), including loss due to blood donation, within 2 months prior to Visit 1 (Screening), or is planning to donate blood during the study.
  11. Has known immune system based allergies or hypersensitivity to any component of study treatment. A history of gastrointestinal intolerance to metformin is not exclusionary.
  12. Is employed by Elcelyx Therapeutics, Inc. (that is an employee, contract worker, or designee of the company).
  13. Has a fasting plasma glucose value >270 mg/dL at Visit 1 (Screening), Visit 2 (Week -2), and an unscheduled visit to be completed within 1 week following Visit 2. The unscheduled visit is to be completed only for subjects with a fasting plasma glucose value >270 mg/dL at Visit 1 and Visit 2.

Sites / Locations

  • Pinnacle Research Group, LLC
  • Central Alabama Research
  • Achieve Clinical Research, LLC
  • University of Alabama at Birmingham
  • Terence T. Hart, MD
  • Radiant Research - Phoenix
  • Arrowhead Health Centers
  • Holland Center for Family Health, LTD
  • Elite Clinical Studies
  • Thunderbird Internal Medicine - Indian School Rd.
  • Clinical Research Institute of Arizona, LLC
  • Summit Clinical Trials Center
  • Searcy Medical Center
  • Advanced Metabolic Care & Research Institute (AMCR)
  • MD Studies, Inc.
  • National Research Institute
  • Scripps Whittier Diabetes Institute
  • Clinical Trials Research
  • Collaborative Neuroscience Network, LLC
  • National Research Institute
  • Catalina Research Institute
  • SRSD, Inc. dba Synergy San Diego
  • Providence Clinical Research
  • Pacific Research Partners, LLC
  • SDS Clinical Trials, Inc.
  • Center for Clinical Trials of Sacramento
  • Center for Clinical Trials of Scaramento
  • Superior Research LLC
  • Syrentis Clinical Research (formerly Research Across America)
  • Encompass Clinical Research
  • Clinical Trial Investigators
  • Infosphere Clinical Research
  • Colorado Springs Health Partners
  • Creekside Endocrine Associates
  • Meridien Research - Brooksville
  • ALL Medical Research, LLC
  • Neostart Corporation dba AGA Clinical Trials
  • Care Partners Clinical Research
  • Health Awareness, Inc.
  • Family Health Care Clinical Studies
  • Clinical Research of Central Florida-Lakeland
  • Clinical Pharmacology of Miami, Inc.
  • Tellus Clinical Research, Inc.
  • Internal Research Associates LLC - Breton
  • Clinical Neuroscience Solutions, Inc. Healthcare Orlando
  • Ormond Medical Arts Pharmaceutical Research Center
  • Private Practice - Andres Patron, DO
  • Progressive Medical Research
  • Meridien Reserach - St. Petersburg
  • Clinical Reserch Trials of Florida
  • Meridien Research - Tampa
  • Metabolic Research Institute, Inc.
  • Biofortis, Inc.
  • AMR Sakeena Research
  • Cedar-Crosse Research Center
  • Evanston Premier Healthcare Research LLC
  • Buynak Clinical Research, PC
  • The Iowa Clinic; Cardiovascular Services
  • Heartland Research Associates, LLC - Augusta
  • Cotton-O'Neil Clinical Research Center
  • Otrimed
  • Kentucky Diabetes Endocrinology Center
  • Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
  • Four Rivers Clinical Research
  • Avant Research Associates
  • Centex Studies, Inc. - lake Charles
  • Columbia Medical Practice
  • Medstar Health Research Institute
  • MD Medical Research
  • Beacon Clinical Research
  • Radiant Research - Edina
  • Planters Clinic
  • Mercury Street Medical Group, PLLC
  • Quality Clinical Research, Inc.
  • Heartland Clinical Research
  • Alliance Against Diabetes
  • AB Clinical Trials
  • Palm Medical Research
  • Ingham Neuroscience Group, LLC
  • Comprehensive Clinical Research
  • Albuquerque Clinical Trials
  • Albuquerque Neuroscience, Inc.
  • NY Scientific
  • Long Island Gastrointestinal Research Group
  • Mid-Hudson Medical Research, PLLC
  • Great Lakes Medical Research
  • PharmQuest
  • Triad Clinical Trials LLC
  • PMG Research of Rocky Mount
  • PMG Research of Salisbury, LLC
  • PMG Research of Wilmington, LLC
  • Sterling Research Group, Ltd
  • Metabolic Atherosclerosis Research Center
  • New Horizons Clinical Research
  • Urgent Care Specialists, LLC DBA Hometown Urgent Care and Occupational Health
  • Prestige Clinical Research
  • Hometown Urgent Care and Research - Huber Heights
  • RAS Health LTD
  • Summit Reserach Group, LLC
  • COR Clinical Research, LLC
  • Willamette Valley Clinical Studies
  • Brandywine Clinical Research
  • Medical Research South, LLC
  • Mountain View Clinical Research - Greer
  • PMG of Charleston, LLC
  • Family Medicine of SayeBrook, LLC
  • Hillcrest Clinical Research, LLC
  • Palmetto Proactive Healthcare, LLC
  • Spartanburg Medical Research
  • Palmetto Clinical Research
  • PMG Research of Bristol, LC - State
  • PMG Research of Knoxville
  • Clinical Neuroscience Solutions, Inc. - Memphis
  • Trinity Clinical Research
  • Central Texas Clinical Research
  • Trinity Universal Research Associates, Inc.
  • Dallas Diabetes and Endocrine Center
  • Research Institute of Dallas
  • Galenos Research
  • Pioneer Research Solutions, Inc.
  • Centex Studies, Inc.
  • Clinical Trial Network - Houston
  • Juno Research, LLC-Houston
  • Juno Research, LLC-Katy
  • Texas Diabetes Institute Research Center
  • Sun Research Institute
  • Victorium Clinical Research
  • Consano Clinical Research
  • Southwest Health Associates, P.A.
  • Chrysalis Clinical Research
  • Burke Internal Medicine & Research
  • Manassas Clinical Research Center
  • Clinical Research Partners, LLC
  • Universal Research Group, LLC
  • Puerto Rico Renal and Health Research, Inc.
  • Advanced Medical Concepts
  • Manati Center for Clinical Reserach Doctor's Center Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm Type

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Placebo Comparator

Active Comparator

Arm Label

600 mg Met DR qAM

900 mg Met DR qAM

1200 mg Met DR qAM

1500 mg Met DR qAM

Placebo-1

Placebo-2

2000 mg Met IR

Arm Description

600 mg metformin delayed-release once daily in the morning

900 mg metformin delayed-release once daily in the morning

1200 mg metformin delayed-release once daily in the morning

1500 mg metformin delayed-release once daily in the morning

placebo match for 600 and 1200 mg Met DR qAM treatment groups

placebo match for 900 and 1500 mg Met DR qAM treatment groups

1000 mg metformin immediate-release twice daily

Outcomes

Primary Outcome Measures

Change in HbA1c (%) at 16 Weeks

Secondary Outcome Measures

Full Information

First Posted
August 16, 2015
Last Updated
March 27, 2018
Sponsor
Elcelyx Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02526524
Brief Title
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM
Official Title
Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled, Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release In Subjects With Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
September 2015 (undefined)
Primary Completion Date
September 2016 (Actual)
Study Completion Date
September 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Elcelyx Therapeutics, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to compare the glycemic effects of delayed-release metformin (Met DR) to placebo in subjects with type 2 diabetes mellitus (T2DM) over 16 weeks. The study is designed to evaluate several doses of Met DR (600 to 1500 mg once daily in the morning [qAM]) compared to placebo. A single-blind reference treatment of 2000 mg metformin immediate-release (Met IR) per day administered as equal divided doses (1000 mg Met IR BID) will also be included.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
571 (Actual)

8. Arms, Groups, and Interventions

Arm Title
600 mg Met DR qAM
Arm Type
Experimental
Arm Description
600 mg metformin delayed-release once daily in the morning
Arm Title
900 mg Met DR qAM
Arm Type
Experimental
Arm Description
900 mg metformin delayed-release once daily in the morning
Arm Title
1200 mg Met DR qAM
Arm Type
Experimental
Arm Description
1200 mg metformin delayed-release once daily in the morning
Arm Title
1500 mg Met DR qAM
Arm Type
Experimental
Arm Description
1500 mg metformin delayed-release once daily in the morning
Arm Title
Placebo-1
Arm Type
Placebo Comparator
Arm Description
placebo match for 600 and 1200 mg Met DR qAM treatment groups
Arm Title
Placebo-2
Arm Type
Placebo Comparator
Arm Description
placebo match for 900 and 1500 mg Met DR qAM treatment groups
Arm Title
2000 mg Met IR
Arm Type
Active Comparator
Arm Description
1000 mg metformin immediate-release twice daily
Intervention Type
Drug
Intervention Name(s)
Met DR
Intervention Description
metformin delayed-release tablets
Intervention Type
Drug
Intervention Name(s)
Met IR
Intervention Description
metformin immediate-release tablets
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change in HbA1c (%) at 16 Weeks
Time Frame
Baseline and 16 weeks after the first dose of study medication

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Is at least 25 years old at Visit 1 (Screening). Is male, or is female and meets all of the following criteria: Not breastfeeding Negative pregnancy test result at Visit 1 (not applicable to post-menopausal or surgically sterile females) Surgically sterile, postmenopausal, or if of childbearing potential, must practice and be willing to continue to practice appropriate birth control during the entire duration of the study. Body mass index (BMI) 20.0 to 45.0 kg/m² (inclusive) at Visit 1 (Screening). Has a physical examination with no clinically significant abnormalities as judged by the investigator. Has T2DM and an HbA1c of 7.5% to 10.5%, inclusive, at Visit 1. Has an estimated glomerular filtration rate (eGFR) value of ≥60 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation. Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 3 months prior to Visit 1: Thiazolidinedione, sulfonylurea, dipeptidyl peptidase-4 inhibitors, and alpha-glucosidase inhibitors Hormone replacement therapy (female subjects) and testosterone (male subjects) Oral contraceptives (female subjects) Antihypertensive agents Lipid-lowering agents Thyroid replacement therapy Antidepressant agents Ability to understand and willingness to adhere to protocol requirements. Exclusion Criteria: Has a clinically significant medical condition as judged by the investigator that could potentially affect study participation and/or personal well-being, including but not limited to the following conditions: Hepatic disease Gastrointestinal disease Endocrine disorder (T2DM is allowed) Cardiovascular disease Central nervous system diseases Psychiatric or neurological disorders Organ transplantation Chronic or acute infection Orthostatic hypotension, fainting spells or blackouts Allergy or hypersensitivity. A history of diabetic ketoacidosis or hyperosmolar non-ketotic hyperglycemia within the past year. Prior major surgery of any kind within 6 months of Visit 1. A history of >3% weight change within 3 months of Visit 1. A clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormality, other than that related to T2DM, judged by the investigator to be clinically significant at Visit 1. An alanine aminotransferase or aspartate aminotransferase result >2.5 × upper limit of normal (ULN) or a bilirubin result >1.5 × ULN. A physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study. Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following excluded medications: Metformin within 2 months of Visit 1 (Screening) Insulin within 2 weeks of Visit 1 (Screening) or for more than 1 week within 3 months of Visit 1 (Screening) Glucagon-like peptide-1 receptor agonists or sodium-glucose co-transporter 2 inhibitors within 3 months of Visit 1 Drugs known to affect body weight, including prescription medications and over-the-counter anti obesity agents within 3 months of Visit 1. Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption within 3 months of Visit 1 Planned use of any drug treatment that affects gastric pH (prescription or over-the-counter), such as H2-receptor antagonists and proton pump inhibitors, after Visit 2 (Week -2), or planned chronic use of any antacids (i.e., more than twice per week) after Visit 2 (Week -2) Cationic drugs that are eliminated by renal tubular secretion within 1 week of Visit 1. Iodinated contrast dye within 1 week prior to Visit 1. Investigational drug within 2 months (or five half-lives of the investigational drug, whichever is greater) of the date of the first dose of randomized study medication. Met DR or double-blind matching placebo for Met DR at any time prior to Visit 1 (Screening) Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures. Had a blood transfusion or experienced significant blood loss (i.e., >500 mL), including loss due to blood donation, within 2 months prior to Visit 1 (Screening), or is planning to donate blood during the study. Has known immune system based allergies or hypersensitivity to any component of study treatment. A history of gastrointestinal intolerance to metformin is not exclusionary. Is employed by Elcelyx Therapeutics, Inc. (that is an employee, contract worker, or designee of the company). Has a fasting plasma glucose value >270 mg/dL at Visit 1 (Screening), Visit 2 (Week -2), and an unscheduled visit to be completed within 1 week following Visit 2. The unscheduled visit is to be completed only for subjects with a fasting plasma glucose value >270 mg/dL at Visit 1 and Visit 2.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Juan P Frias, MD
Organizational Affiliation
National Research Institute - Wilshire
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pinnacle Research Group, LLC
City
Anniston
State/Province
Alabama
ZIP/Postal Code
36207
Country
United States
Facility Name
Central Alabama Research
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35209
Country
United States
Facility Name
Achieve Clinical Research, LLC
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35216
Country
United States
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
Terence T. Hart, MD
City
Tuscumbia
State/Province
Alabama
ZIP/Postal Code
35674
Country
United States
Facility Name
Radiant Research - Phoenix
City
Chandler
State/Province
Arizona
ZIP/Postal Code
85224
Country
United States
Facility Name
Arrowhead Health Centers
City
Glendale
State/Province
Arizona
ZIP/Postal Code
85306
Country
United States
Facility Name
Holland Center for Family Health, LTD
City
Peoria
State/Province
Arizona
ZIP/Postal Code
85381
Country
United States
Facility Name
Elite Clinical Studies
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85018
Country
United States
Facility Name
Thunderbird Internal Medicine - Indian School Rd.
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85037
Country
United States
Facility Name
Clinical Research Institute of Arizona, LLC
City
Surprise
State/Province
Arizona
ZIP/Postal Code
85374
Country
United States
Facility Name
Summit Clinical Trials Center
City
Fayetteville
State/Province
Arkansas
ZIP/Postal Code
72703
Country
United States
Facility Name
Searcy Medical Center
City
Searcy
State/Province
Arkansas
ZIP/Postal Code
72143
Country
United States
Facility Name
Advanced Metabolic Care & Research Institute (AMCR)
City
Escondido
State/Province
California
ZIP/Postal Code
92025
Country
United States
Facility Name
MD Studies, Inc.
City
Fountain Valley
State/Province
California
ZIP/Postal Code
92708
Country
United States
Facility Name
National Research Institute
City
Huntington Park
State/Province
California
ZIP/Postal Code
90255
Country
United States
Facility Name
Scripps Whittier Diabetes Institute
City
La Jolla
State/Province
California
ZIP/Postal Code
92037
Country
United States
Facility Name
Clinical Trials Research
City
Lincoln
State/Province
California
ZIP/Postal Code
95648
Country
United States
Facility Name
Collaborative Neuroscience Network, LLC
City
Long Beach
State/Province
California
ZIP/Postal Code
90806
Country
United States
Facility Name
National Research Institute
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Catalina Research Institute
City
Montclair
State/Province
California
ZIP/Postal Code
91763
Country
United States
Facility Name
SRSD, Inc. dba Synergy San Diego
City
National City
State/Province
California
ZIP/Postal Code
91950
Country
United States
Facility Name
Providence Clinical Research
City
North Hollywood
State/Province
California
ZIP/Postal Code
91606
Country
United States
Facility Name
Pacific Research Partners, LLC
City
Oakland
State/Province
California
ZIP/Postal Code
94607
Country
United States
Facility Name
SDS Clinical Trials, Inc.
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Center for Clinical Trials of Sacramento
City
Sacramento
State/Province
California
ZIP/Postal Code
95823
Country
United States
Facility Name
Center for Clinical Trials of Scaramento
City
Sacramento
State/Province
California
ZIP/Postal Code
95823
Country
United States
Facility Name
Superior Research LLC
City
Sacramento
State/Province
California
ZIP/Postal Code
95825
Country
United States
Facility Name
Syrentis Clinical Research (formerly Research Across America)
City
Santa Ana
State/Province
California
ZIP/Postal Code
92705
Country
United States
Facility Name
Encompass Clinical Research
City
Spring Valley
State/Province
California
ZIP/Postal Code
91978
Country
United States
Facility Name
Clinical Trial Investigators
City
Tustin
State/Province
California
ZIP/Postal Code
92780
Country
United States
Facility Name
Infosphere Clinical Research
City
Van Nuys
State/Province
California
ZIP/Postal Code
91405
Country
United States
Facility Name
Colorado Springs Health Partners
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80906
Country
United States
Facility Name
Creekside Endocrine Associates
City
Denver
State/Province
Colorado
ZIP/Postal Code
80209
Country
United States
Facility Name
Meridien Research - Brooksville
City
Brooksville
State/Province
Florida
ZIP/Postal Code
34601
Country
United States
Facility Name
ALL Medical Research, LLC
City
Cooper City
State/Province
Florida
ZIP/Postal Code
33024
Country
United States
Facility Name
Neostart Corporation dba AGA Clinical Trials
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33012
Country
United States
Facility Name
Care Partners Clinical Research
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32277
Country
United States
Facility Name
Health Awareness, Inc.
City
Jupiter
State/Province
Florida
ZIP/Postal Code
33458
Country
United States
Facility Name
Family Health Care Clinical Studies
City
Kissimmee
State/Province
Florida
ZIP/Postal Code
34741
Country
United States
Facility Name
Clinical Research of Central Florida-Lakeland
City
Lakeland
State/Province
Florida
ZIP/Postal Code
33810
Country
United States
Facility Name
Clinical Pharmacology of Miami, Inc.
City
Miami
State/Province
Florida
ZIP/Postal Code
33014
Country
United States
Facility Name
Tellus Clinical Research, Inc.
City
Miami
State/Province
Florida
ZIP/Postal Code
33173
Country
United States
Facility Name
Internal Research Associates LLC - Breton
City
Miami
State/Province
Florida
ZIP/Postal Code
33183
Country
United States
Facility Name
Clinical Neuroscience Solutions, Inc. Healthcare Orlando
City
Orlando
State/Province
Florida
ZIP/Postal Code
32801
Country
United States
Facility Name
Ormond Medical Arts Pharmaceutical Research Center
City
Ormond Beach
State/Province
Florida
ZIP/Postal Code
32174
Country
United States
Facility Name
Private Practice - Andres Patron, DO
City
Pembroke Pines
State/Province
Florida
ZIP/Postal Code
33026
Country
United States
Facility Name
Progressive Medical Research
City
Port Orange
State/Province
Florida
ZIP/Postal Code
32127
Country
United States
Facility Name
Meridien Reserach - St. Petersburg
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33709
Country
United States
Facility Name
Clinical Reserch Trials of Florida
City
Tampa
State/Province
Florida
ZIP/Postal Code
33607
Country
United States
Facility Name
Meridien Research - Tampa
City
Tampa
State/Province
Florida
ZIP/Postal Code
33634
Country
United States
Facility Name
Metabolic Research Institute, Inc.
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33401
Country
United States
Facility Name
Biofortis, Inc.
City
Addison
State/Province
Illinois
ZIP/Postal Code
60101
Country
United States
Facility Name
AMR Sakeena Research
City
Aurora
State/Province
Illinois
ZIP/Postal Code
60506
Country
United States
Facility Name
Cedar-Crosse Research Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60607
Country
United States
Facility Name
Evanston Premier Healthcare Research LLC
City
Evanston
State/Province
Illinois
ZIP/Postal Code
60201
Country
United States
Facility Name
Buynak Clinical Research, PC
City
Valparaiso
State/Province
Indiana
ZIP/Postal Code
46383
Country
United States
Facility Name
The Iowa Clinic; Cardiovascular Services
City
West Des Moines
State/Province
Iowa
ZIP/Postal Code
50266
Country
United States
Facility Name
Heartland Research Associates, LLC - Augusta
City
Augusta
State/Province
Kansas
ZIP/Postal Code
67010
Country
United States
Facility Name
Cotton-O'Neil Clinical Research Center
City
Topeka
State/Province
Kansas
ZIP/Postal Code
66606
Country
United States
Facility Name
Otrimed
City
Edgewood
State/Province
Kentucky
ZIP/Postal Code
41017
Country
United States
Facility Name
Kentucky Diabetes Endocrinology Center
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40503
Country
United States
Facility Name
Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40213
Country
United States
Facility Name
Four Rivers Clinical Research
City
Paducah
State/Province
Kentucky
ZIP/Postal Code
42003
Country
United States
Facility Name
Avant Research Associates
City
Crowley
State/Province
Louisiana
ZIP/Postal Code
70526
Country
United States
Facility Name
Centex Studies, Inc. - lake Charles
City
Lake Charles
State/Province
Louisiana
ZIP/Postal Code
70601
Country
United States
Facility Name
Columbia Medical Practice
City
Columbia
State/Province
Maryland
ZIP/Postal Code
21045
Country
United States
Facility Name
Medstar Health Research Institute
City
Hyattsville
State/Province
Maryland
ZIP/Postal Code
20782
Country
United States
Facility Name
MD Medical Research
City
Oxon Hill
State/Province
Maryland
ZIP/Postal Code
20745
Country
United States
Facility Name
Beacon Clinical Research
City
Quincy
State/Province
Massachusetts
ZIP/Postal Code
02169
Country
United States
Facility Name
Radiant Research - Edina
City
Edina
State/Province
Minnesota
ZIP/Postal Code
55435
Country
United States
Facility Name
Planters Clinic
City
Port Gibson
State/Province
Mississippi
ZIP/Postal Code
39150
Country
United States
Facility Name
Mercury Street Medical Group, PLLC
City
Butte
State/Province
Montana
ZIP/Postal Code
59701
Country
United States
Facility Name
Quality Clinical Research, Inc.
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68114
Country
United States
Facility Name
Heartland Clinical Research
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68134
Country
United States
Facility Name
Alliance Against Diabetes
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89101
Country
United States
Facility Name
AB Clinical Trials
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89119
Country
United States
Facility Name
Palm Medical Research
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89128
Country
United States
Facility Name
Ingham Neuroscience Group, LLC
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89146
Country
United States
Facility Name
Comprehensive Clinical Research
City
Berlin
State/Province
New Jersey
ZIP/Postal Code
08009
Country
United States
Facility Name
Albuquerque Clinical Trials
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87102
Country
United States
Facility Name
Albuquerque Neuroscience, Inc.
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87109
Country
United States
Facility Name
NY Scientific
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11235
Country
United States
Facility Name
Long Island Gastrointestinal Research Group
City
Great Neck
State/Province
New York
ZIP/Postal Code
11023
Country
United States
Facility Name
Mid-Hudson Medical Research, PLLC
City
Hopewell Junction
State/Province
New York
ZIP/Postal Code
12533
Country
United States
Facility Name
Great Lakes Medical Research
City
Westfield
State/Province
New York
ZIP/Postal Code
14787
Country
United States
Facility Name
PharmQuest
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27408
Country
United States
Facility Name
Triad Clinical Trials LLC
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27410
Country
United States
Facility Name
PMG Research of Rocky Mount
City
Rocky Mount
State/Province
North Carolina
ZIP/Postal Code
27804
Country
United States
Facility Name
PMG Research of Salisbury, LLC
City
Salisbury
State/Province
North Carolina
ZIP/Postal Code
28144
Country
United States
Facility Name
PMG Research of Wilmington, LLC
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28401
Country
United States
Facility Name
Sterling Research Group, Ltd
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Facility Name
Metabolic Atherosclerosis Research Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45227
Country
United States
Facility Name
New Horizons Clinical Research
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45242
Country
United States
Facility Name
Urgent Care Specialists, LLC DBA Hometown Urgent Care and Occupational Health
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43214
Country
United States
Facility Name
Prestige Clinical Research
City
Franklin
State/Province
Ohio
ZIP/Postal Code
45005
Country
United States
Facility Name
Hometown Urgent Care and Research - Huber Heights
City
Huber Heights
State/Province
Ohio
ZIP/Postal Code
45424
Country
United States
Facility Name
RAS Health LTD
City
Marion
State/Province
Ohio
ZIP/Postal Code
43302
Country
United States
Facility Name
Summit Reserach Group, LLC
City
Stow
State/Province
Ohio
ZIP/Postal Code
44224
Country
United States
Facility Name
COR Clinical Research, LLC
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73103
Country
United States
Facility Name
Willamette Valley Clinical Studies
City
Eugene
State/Province
Oregon
ZIP/Postal Code
97404
Country
United States
Facility Name
Brandywine Clinical Research
City
Downingtown
State/Province
Pennsylvania
ZIP/Postal Code
19335
Country
United States
Facility Name
Medical Research South, LLC
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29407
Country
United States
Facility Name
Mountain View Clinical Research - Greer
City
Greer
State/Province
South Carolina
ZIP/Postal Code
29651
Country
United States
Facility Name
PMG of Charleston, LLC
City
Mount Pleasant
State/Province
South Carolina
ZIP/Postal Code
29464
Country
United States
Facility Name
Family Medicine of SayeBrook, LLC
City
Myrtle Beach
State/Province
South Carolina
ZIP/Postal Code
29588
Country
United States
Facility Name
Hillcrest Clinical Research, LLC
City
Simpsonville
State/Province
South Carolina
ZIP/Postal Code
29681
Country
United States
Facility Name
Palmetto Proactive Healthcare, LLC
City
Spartanburg
State/Province
South Carolina
ZIP/Postal Code
29301
Country
United States
Facility Name
Spartanburg Medical Research
City
Spartanburg
State/Province
South Carolina
ZIP/Postal Code
29303
Country
United States
Facility Name
Palmetto Clinical Research
City
Summerville
State/Province
South Carolina
ZIP/Postal Code
29485
Country
United States
Facility Name
PMG Research of Bristol, LC - State
City
Bristol
State/Province
Tennessee
ZIP/Postal Code
37620
Country
United States
Facility Name
PMG Research of Knoxville
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37912
Country
United States
Facility Name
Clinical Neuroscience Solutions, Inc. - Memphis
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38119
Country
United States
Facility Name
Trinity Clinical Research
City
Tullahoma
State/Province
Tennessee
ZIP/Postal Code
37388
Country
United States
Facility Name
Central Texas Clinical Research
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Facility Name
Trinity Universal Research Associates, Inc.
City
Carrollton
State/Province
Texas
ZIP/Postal Code
75007
Country
United States
Facility Name
Dallas Diabetes and Endocrine Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
Research Institute of Dallas
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Facility Name
Galenos Research
City
Dallas
State/Province
Texas
ZIP/Postal Code
75251
Country
United States
Facility Name
Pioneer Research Solutions, Inc.
City
Houston
State/Province
Texas
ZIP/Postal Code
77036
Country
United States
Facility Name
Centex Studies, Inc.
City
Houston
State/Province
Texas
ZIP/Postal Code
77058
Country
United States
Facility Name
Clinical Trial Network - Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77074
Country
United States
Facility Name
Juno Research, LLC-Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77074
Country
United States
Facility Name
Juno Research, LLC-Katy
City
Katy
State/Province
Texas
ZIP/Postal Code
77450
Country
United States
Facility Name
Texas Diabetes Institute Research Center
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78207
Country
United States
Facility Name
Sun Research Institute
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78215
Country
United States
Facility Name
Victorium Clinical Research
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78231
Country
United States
Facility Name
Consano Clinical Research
City
Shavano Park
State/Province
Texas
ZIP/Postal Code
78231
Country
United States
Facility Name
Southwest Health Associates, P.A.
City
Sugar Land
State/Province
Texas
ZIP/Postal Code
77478
Country
United States
Facility Name
Chrysalis Clinical Research
City
Saint George
State/Province
Utah
ZIP/Postal Code
84790
Country
United States
Facility Name
Burke Internal Medicine & Research
City
Burke
State/Province
Virginia
ZIP/Postal Code
22015
Country
United States
Facility Name
Manassas Clinical Research Center
City
Manassas
State/Province
Virginia
ZIP/Postal Code
20110
Country
United States
Facility Name
Clinical Research Partners, LLC
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23235
Country
United States
Facility Name
Universal Research Group, LLC
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Facility Name
Puerto Rico Renal and Health Research, Inc.
City
Carolina
ZIP/Postal Code
00987
Country
Puerto Rico
Facility Name
Advanced Medical Concepts
City
Cidra
ZIP/Postal Code
00736
Country
Puerto Rico
Facility Name
Manati Center for Clinical Reserach Doctor's Center Hospital
City
Manati
ZIP/Postal Code
00674
Country
Puerto Rico

12. IPD Sharing Statement

Citations:
PubMed Identifier
30252913
Citation
Henry RR, Frias JP, Walsh B, Skare S, Hemming J, Burns C, Bicsak TA, Baron A, Fineman M. Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes. PLoS One. 2018 Sep 25;13(9):e0203946. doi: 10.1371/journal.pone.0203946. eCollection 2018.
Results Reference
derived

Learn more about this trial

Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM

We'll reach out to this number within 24 hrs